Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRAdHIVNE1
- Development stage
- Phase 1
- Lead developer
- ReiThera
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**GRAdHIVNE1** is a prophylactic vaccine candidate utilizing a non-replicating gorilla adenovirus (GRAd) vector (GRAd32) to deliver highly networked HIV T-cell epitopes. Developed collaboratively by ReiThera (providing the GRAd platform), the Ragon Institute (immunogen design targeting vulnerable HIV structural regions), and IAVI (sponsoring the trial), it aims to induce potent CD8+ T-cell responses for HIV prevention and potential therapeutic use. Currently in a Phase 1 trial (IAVI C114, NCT06617091) evaluating safety, tolerability, and immunogenicity in ~120 healthy adults and virally suppressed people living with HIV in South Africa and Zimbabwe.[1][2][3]
- Other names
- Gorilla Adenovirus Vectored Networked Epitopes VaccineGorilla Adenovirus Vectored HIV Networked Epitopes Vaccinegorilla-isolated adenovirus (GRAd32) vector
Beyond the preview
Go deeper on GRAdHIVNE1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRAdHIVNE1.